InCircle Review aligns longitudinal patient, diagnostic, and insurance data to streamline the prescribing process and help ensure patients receive the right drug at the right time while providing consistent and transparent decision-making for all stakeholders.

By leveraging the knowledge of a panel of expert reviewers who have access to real data, InCircle Review alleviates the burden on prescribing physicians who are currently tasked with making accurate diagnoses without access to the data and longitudinal records to do so.

In addition, InCircle Review gives payors a transparent and consistent view of the decision-making process, while providing employers with a desperately needed solution to control drug spend.

InCircle Review combines the knowledge of key opinion leaders with the data needed to make the right prescribing decision, lowering rates of misdiagnosis and prescription overutilization.

Developed by leading neuromuscular physicians Jonathan Katz, M.D., and Todd Levine, M.D., InCircle Review helps payors and MCOs improve care, minimize waste, and decrease drug spend for expensive therapies like Intravenous Immunoglobulin Therapy (IVIg) with the help of a proprietary algorithm-based approach to match the right drug with the right patient.

We provide transparent and consistent communication that minimizes misdiagnosis and improves clinical outcomes for patients with complex neurological disorders.

The idea for InCircle Review followed the findings of the largest review of immunoglobulin specialty drug therapy utilization.

The INSIGHTS study included a review of 248 patient progress notes, lab data, and electrodiagnostic studies supplied to insurance companies for IVIG in neuropathy. The compiled data, which included referrals from 154 physicians in 26 states, produced findings that were troubling:

• Only 32% of patients receiving treatment were determined to actually have an immune neuropathy
• Half of patients diagnosed with neuropathies that were clearly not immune-mediated
• Only 15% clearly met electrodiagnostic criteria for a demyelinating neuropathy

So, we set out to create a solution that would be better for insurers, providers, and patients.

Spurred by a desire to improve IG prescription accuracy, the core team at InCircle Review began strategizing to develop an algorithm-based approach that would capture only the most vital patient data and essentially match the right drug to the right patient.

The InCircle Review solution eliminates the need to involve MDs in the decision-making process, while leveraging the experience and knowledge of a panel of expert reviewers who have access to real data.

InCircle Review is poised to revolutionize the cumbersome IG review process, deliver longitudinal patient tracking information,
provide open access to accurate data, and fundamentally transform the way IG is prescribed.

It also facilitates a significant process improvement by shortening the time for approvals, ultimately reducing the overall drug spend – a win-win for physicians, payors and specialty drug manufacturers.